CSL Research Acceleration Initiative

Applications close 23rd February 2023

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL’s therapeutic areas.

Successful applicants will receive up to $400k over 2 years. Researchers who wish to apply are required to submit a non-confidential, 300 word online abstract by 23rd February 2023.

Interested researchers are invited to join an online information session to learn more. Webinars will be held on Weds 25th January 1pm ET/12pm CT/11am MT/10am PT or Mon 6th February 4pm ET/3pm CT/2pm MT/1pm PT.

For webinar links and online application instructions, please contact Ying-Li Chen (ying-li.chen@stanford.edu).

The 2023 Research Acceleration Initiative will focus on research proposals that align with a CSL Therapeutic Area and are amenable to or include a Modality as illustrated below. Please see over page for specific Focus Areas.

For further information or to apply, please contact Ying-Li Chen (ying-li.chen@stanford.edu).
CSL Research Acceleration Initiative

Focus Areas

CSL is seeking applications that align with a CSL Therapeutic Area and are amenable to include a CSL Modality in the following Focus Areas:

**IMMUNOLOGY**

Autoimmune diseases (AID)
- Novel targets or biologic therapies for the treatment of AIDs including primary Sjögren's syndrome, systemic sclerosis, inflammatory idiopathic myopathies (including dermatomyositis) and autoimmune skin blistering diseases. We are seeking:
  - Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF-family members
  - Novel targets or biologic therapies involved in B cell depletion or B cell regulation
  - Novel targets or biologic therapies involved in T cell regulation, T cell tolerance and T regulatory cell modulation

Alternatives to plasma-derived intravenous immunoglobulin (IVIG)
- Synthetic or recombinant solutions to IVIG that are independent of plasma

**HEMATOLOGY**

Hemorrhagic stroke
- Novel biologic targets or therapies for the treatment of subarachnoid hemorrhage and intracerebral hemorrhage
- Biomarker or omics approaches for patient stratification and drug discovery

Acute ischemic stroke
- Novel biologic targets or therapies for the treatment of acute ischemic stroke, in particular anti-(thrombo-) inflammatory approaches as an adjunct to endovascular thrombectomy and pharmacological thrombolysis (tPA)
- Biomarker or omics approaches for patient stratification and drug discovery

Acute thrombosis (venous and arterial thrombosis)
- Novel biologic therapies for targeted fibrinolysis / thrombolysis with increased safety and / or efficacy vs. standard of care in acute thrombotic conditions, in particular acute ischemic stroke and pulmonary embolism

**RESPIRATORY**

Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
- Novel biologic therapies or targets to treat IPF and PPF
- Omics approaches for patient stratification and drug discovery

Community acquired pneumonia (CAP)-associated complications
- Novel biologic therapies or targets to treat CAP-associated complications including acute respiratory distress syndrome (ARDS), sepsis, and acute kidney injury (AKI)
- Omics approaches for patient stratification and drug discovery

**VACCINES**

mRNA and lipid nanoparticle platform
- Innovative research addressing improved delivery, formulation, stabilization (5°C / room temperature), shelf-life extension and manufacturing technologies

Influenza virus antigen purity and yield enhancement
- Innovative research with potential to impact yield and purity of influenza virus HA antigen produced in MDCK cell culture

Proven adjuvant technology
- Partnerships with our proprietary adjuvant MF59®

**GENE THERAPY**

- In vivo kill switch or suicide switch
- Modulation of transgene expression in vivo
- Novel methods to select gene modified hematopoietic stem cells
- Novel gene therapies or gene therapy targets aligned with CSL’s Therapeutic Areas
- Non-viral in vivo delivery of ribonucleoproteins

**CARDIOVASCULAR AND METABOLIC**

Myocarditis
- Novel targets or biologic therapies for myocarditis

Dilated cardiomyopathy
- Novel targets or biologic therapies for inflammatory dilated cardiomyopathy

Rare lipid disorders
- Novel targets or biologic therapies (including gene therapies) for rare lipid disorders e.g. homozygous familial hypercholesterolemia

Severe forms of atherosclerosis
- Novel targets or biologic therapies for severe atherosclerosis

**TRANSPLANT**

Chronic lung allograft dysfunction (CLAD)
- Novel biologic therapies or targets to prevent or treat CLAD, including approaches to establish tolerance / novel immunomodulation strategies
- Novel biomarkers for CLAD

Hematopoietic stem cell transplant (HSCT)
- Novel biologic therapies for the treatment and prevention of acute and chronic GvHD, including approaches to establish tolerance / novel immunomodulation strategies
- Novel biologic therapies that improve efficacy / safety of HSCT

Cardiovascular allograft vasculopathy (CAV)
- Novel biologic therapies for the treatment of CAV
- Animal models of CAV

**ORAL DELIVERY**

Technologies enabling oral delivery of biologics (e.g. antibodies and other protein therapeutics)

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail RAI@csl.com.au to discuss.